Fox Chase Cancer Center | Strategic Alliance Partners

October 26, 2020

Hossein Borghaei, DO, MS, further discusses the benefit of immunotherapy combinations, the potential of tiragolumab, and the need for better biomarkers to guide treatment in NSCLC.

October 25, 2020

After 15 years as a surgeon, Jeffrey M. Farma, MD, says he's still learning how to treat patients with cancer. As fellowship director of the Complex General Surgical Oncology Fellowship at Fox Chase Cancer Center, he expects his trainees to be prepared to do the same.

October 21, 2020

John A. Abraham, MD, FACS, discusses remaining questions with pexidartinib in tenosynovial giant cell tumor.

October 20, 2020

John A. Abraham, MD, FACS, discusses the clinical utility of pexidartinib in tenosynovial giant cell tumor.

October 02, 2020

John A. Abraham, MD, FACS, discusses the surgical management of patients with tenosynovial giant cell tumor.

April 30, 2020

John A. Abraham, MD, FACS, discusses potential symptoms of tenosynovial giant cell tumor.

April 03, 2020

Hossein Borghaei, DO, MS, discusses the impact of COVID-19 on clinical practice and projected how the virus will change practice for the better in the long term.

March 03, 2020

February 19, 2020

We traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit™ on Lung Cancer, which featured insights from the UPMC and Fox Chase Cancer Center faculty.

January 29, 2020

Hossein Borghaei, DO, MS, discusses immunotherapy alone or in combination with chemotherapy in combination with immunotherapy in patients with advanced NSCLC.

January 03, 2020

Hossein Borghaei, DO, MS, discusses immune-related adverse events in patients with lung cancer who received immunotherapy/chemotherapy combinations.

November 16, 2019

Hossein Borghaei, DO, MS, discusses emerging biomarkers of response to immunotherapy in non–small cell lung cancer (NSCLC).

October 17, 2019

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, professor, Department of Hematology/Oncology, co-director, Immune Monitoring Facility, Lung Cancer and Mesothelioma TRDG member, and Gloria and Edmund M. Dunn Chair in Thoracic Oncology, Fox Chase Cancer Center, discusses the clinical utility of PD-L1 in advanced non–small cell lung cancer (NSCLC).

October 05, 2019

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses necessary research and anticipated trials evaluating immunotherapy in advanced non–small cell lung cancer (NSCLC).

October 02, 2019

Robert G. Uzzo, MD, MBA, FACS, discusses the evolving yet relevant role of surgery in renal cell carcinoma.

October 01, 2019

Robert G. Uzzo, MD, MBA, FACS, discusses the evolving role of surgery in metastatic kidney cancer.

September 25, 2019

Hossein Borghaei, DO, discusses pivotal and ongoing trials driven by biomarkers in lung cancer.

August 09, 2019

Michael J. Hall, MD, Fox Chase Cancer Center, discusses the emergence of PARP inhibition in the armamentarium for patients with pancreatic cancer.

July 15, 2019

Each year, 10% to 15% of patients with soft-tissue carcinomas receive a diagnosis of rare retroperitoneal sarcoma (RPS), an aggressive disease that typically recurs in 26% of cases and has a 47% to 67% five-year overall survival rate. New radiation therapies hold potential to decrease treatment time and provide local control of RPS.

June 26, 2019

Hossein Borghaei, MD, highlights long-term single-agent pembrolizumab (Keytruda) data and the overall state of immunotherapy in non–small cell lung cancer, as well as the prospect of making clinical trial eligibility less restrictive.